31 results about "Staphylococcus Phages" patented technology

The invention relates to the field of biology, particularly to novel Staphylococcus aureus phages and a composition thereof, and applications of the composition, and provides 4 Staphylococcus aureus phages such as Podoviridae sp .BP-13 with the preservation number of CCTCC NO:M2015142, Staphylococcus aureus phage BP-13A with the preservation number of CCTCC NO:M2016535, Podoviridae sp .BP-14 withthe preservation number of CCTCC NO:M2015143, and Podoviridae picovirinae Ahjdlikevirus BP-39 with the preservation number of CCTCC NO:M2015144. According to the present invention, the four phages arethe strict potent phages, can effectively kill various types of Staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have wide host ranges, and have no toxic effect on normal microbial flora, and the DNA of the phages cannot encode virulence genes, such that the Staphylococcus aureus phages can be used for preventing or treating human and animal bacterial infections caused by Staphylococcus aureus, can provide excellent strain resources for the development of novel antibacterial preparations, and have good application development prospects; and the host range and the antibacterial efficiency of the cocktail mixture of the present invention are further greatly improved.

The invention relates to a bacteriophage and antimicrobial application thereof, in particular to a methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage and antimicrobial application thereof, and belongs to the field of bioengineering. The methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage is preserved in China Center for Type Culture Collection (CCTCC), located in Wuhan University of Wuhan of China, on September 17, 2015. The collection number is staphylococcus aureus bacteriophage qdsa002 of CCTCC M2015554. The Latin scientific name is staphylococcus aureus bacteriophage qdsa002. The bacteriophage has high splitting effect on staphylococcus aureus, especially methicillin-resistant staphylococcus epidermidis staphylococcus aureus. The preparation can be used individually or compounded with other drugs, and a safe bacteriophage product source free of toxic and side effects is provided for control of methicillin-resistant staphylococcus epidermidis staphylococcus aureus contamination.

The invention provides a staphylococcus aureus phage strain VB_SavM_JYL01. The staphylococcus aureus phage stain VB_SavM_JYL01 has been preserved in the China Center for Type Culture Collection on 25th March, 2018, the preservation name is Staphylococcus aureus phage VB_SavM_JYL01, and the preservation number is CCTCC M 2018154. The staphylococcus aureus phage strain has a wide lysis spectrum, thus staphylococcus aureus can be lysed, certain staphylococcus epidermidis can also be lysed, host bacteria 206 can be lysed, and staphylococcus clinical strains separated from the environment or fecesof diseased animals can also be lysed; the staphylococcus aureus phage can be used independently or in combination with other substances, and a safe and nontoxic phage disinfecting and killing productis provided for disinfecting and purifying the environment.

The invention relates to the field of biological engineering, and in particular relates to lywallzyme (or catenase) of phage of staphylococcus aureus and an application thereof as an antibacterial material in preventing and treating bouine mastitis and controlling food pollution. The amino acid sequence of the lywallzyme of phage of staphylococcus aureus is SeqIDNO2. Zymin capable of efficiently killing staphylococcus aureus is developed by a bioengineering technique. The zymin can be used independently or with other agents to inactivate staphylococcus aureus specifically so as to provide a safe zymin source without toxic and side effects for preventing and treating bouine mastitis and controlling staphylococcus aureus pollution in food.

The invention provides a genetic engineering-modified staphylococcus aureus staphylophage lyase, the amino acid sequence of which is shown in SEQ ID NO:1. The invention also discloses a preparation method of the staphylococcus aureus staphylophage lyase, comprising the following concrete steps: (1) cloning the amino acid sequence shown in the SEQ ID NO:1 into a prokaryotic expression vector to obtain a recombinant plasmid; (2) transforming the recombinant plasmid obtained in the step (1) into host bacteria to obtain recombinant bacteria; (3) expressing the staphylococcus aureus staphylophage lyase by the recombinant plasmid; and (4) purifying the staphylococcus aureus staphylophage lyase obtained in the step (3). Multiple staphylococcus aureus can be specifically inactivated by independently using the genetic engineering-modified staphylococcus aureus staphylophage lyase or matching the genetic engineering-modified staphylococcus aureus staphylophage lyase with other compounds, thus providing a safe enzymic preparation source without toxic and side effects for staphylococcus aureus infection, particularly staphylococcus aureus caused dairy mastitis in the existing dairy farm control.

The invention discloses a staphylococcus aureus bacteriophage lyase as well as a preparation method and application thereof, and relates to the technical field of bioengineering. The invention provides a staphylococcus aureus bacteriophage lyase LysSA2, and the amino acid sequence of the LysSA2 is Seq ID NO.1; and the invention provides an encoding gene of the staphylococcus aureus bacteriophage lyase LysSA2, and the nucleotide sequence of the encoding gene is Seq ID NO.2. The invention also provides a preparation method of the staphylococcus aureus bacteriophage lyase LysSA2. The method clones staphylococcus aureus bacteriophage SA2 to obtain the bacteriophage lyase LysSA2, and carries out induced expression on soluble lyase by adopting a prokaryotic expression mode. The bacteriophage lyase LysSA2 not only has a relatively strong bacteriostatic effect on staphylococcus, but also has a broad-spectrum bacteriostatic effect on staphylococcus from different sources, and lays a foundationfor treating and inhibiting staphylococcus diseases.

The invention discloses a recombinant adenovirus capable of co-expressing double antibacterial genes of SAL-2 and hLYZ, and a construction method and application thereof. The construction method includes amplifying the SAL-2 gene and the hLYZ gene from a staphylococcus aureus phage genome and a human milk somatic cell total RNA (ribonucleic acid) respectively, cloning the obtained target genes into a shuttle vector pShuttle-IRES-hrGFP-2, co-transfecting an escherichia coli BJ5183 competent cell by the shuttle vector and a framework vector pAdeasy-1 after linear recombination of the shuttle vector to achieve homologous recombination in BJ5183, and constructing a recombinant adenovirus plasmid AD-SAL-LYZ containing the target genes; transfecting an HEK293 cell through liposome mediation after Pac I digestion of the recombinant adenovirus plasmid, and packing to obtain the high-titer recombinant adenovirus; evaluating the joint inhibiting effect of the SAL-2 gene and the hLYZ gene on main pathogenic bacteria of cow mastitis under adenovirus mediation.

The invention discloses a phage flocculant and application of the phage flocculant in a fermentation post-treatment technology and belongs to the field of a microbial post-treatment technology. The phage flocculant is characterized in that the phage flocculant is a cationic flocculant, and a working concentration of the phage flocculant is 0.1-5% generally. The flocculant is applied in the fermentation post-treatment technology of a vibrio parahaemolyticus phage, a coliphage, a salmonella phage, a xanthomonas axonopodis phage, a ralstonia solanacearum phage, a staphylococcus aureus phage, a streptococcus agalactiae phage, a streptococcus iniae phage or a pseudomonas aeruginosa phage. The phage flocculant can play a role of rapid subsidence of bacteria, be convenient and quick to operate, reduce centrifugal equipment investment and manpower and material resource loss and meet requirements of industrial mass production of the phage, and is safe, nontoxic and harmless to animals and plants.

The invention discloses a phage water aqua preservative, a preparation method and an application thereof and belongs to the technical field of microbial antisepsis. The technical scheme is characterized in that the phage water aqua preservative comprises the following components by weight: 1-3 parts of sodium dehydroacetate, 7-9 parts of preservative and the balance of water aqua. The phage wateraqua preservative is applicable to strains such as a vibrio parahaemolyticus phage, an escherichia coli phage, a salmonella phage, a ralstonia solanacearum phage, a staphylococcus aureus phage, an aeromonas hydrophila phage, the ralstonia solanacearum phage, an axonopus scoparius xanthomonas and an agrobacterium tumefaciens. The preservative disclosed by the invention has the advantages of preventing bacterial growth, being non-toxic to the phages and improving the stability of the phages so that the phages are difficult to deteriorate and the stability of the titer is maintained. In a practical case, the preservative can play a good role in the prevention and control of animal and plant diseases, and is especially applicable to the industrial large-scale production of phage preparations and the process of user storage and field application.

The invention discloses staphylococcus aureus bacteriophage and application. The staphylococcus aureus bacteriophage and the application have the advantages that staphylococcus aureus can be specifically effectively eliminated by the staphylococcus aureus bacteriophage, excellent in-vivo and in-vitro antibacterial effects can be realized by the staphylococcus aureus bacteriophage for medicine-resistant staphylococcus aureus, experimental foundations can be provided to clinically developing preparations for preventing and treating medicine-resistant staphylococcus aureus infection, and the staphylococcus aureus bacteriophage has great clinical application potential; the skin abscess average areas of nude mice of bacteriophage treatment groups are 47.32 mm<2> in skin abscess models when MOI(multiplicity of infection) is equal to 10, and the average bacterium load is 3.553*10<7> CFU / g; the skin abscess average areas of nude mice of MRSA (methicillin-resistant staphylococcus aureus) infection groups are 150.4 mm<2>, and the average bacterium load is 2.284*10<8> CFU / g; the skin abscess areas of the mice of the bacteriophage treatment groups are smaller than the skin abscess areas of the mice of the MRSA infection groups, the colony count of the mice of the bacteriophage treatment groups is lower than the colony count of the mice of the MRSA infection groups, and the difference of the skin abscess areas and the colony count has statistical significance.

The invention relates to the technical field of microorganisms, and particularly relates to a Staphylococcus aureus phage and bacteriostatic application thereof. The Staphylococcus aureus phages107 is sent to China Center for Type Culture Collection for Preservation, the classification name is Staphylococcus aureus phages107, the preservation number is CCTCC NO: M2021125, the preservation date is January 21, 2021, and the address is Wuhan University, Wuhan City, China. The phages107 has high titer up to 2.31 * 10<10>PFU / mL, good pH stability, good temperature stability and wide lysis spectrum, and has lysis ability on 9 strains of Staphylococcus aureus, wherein the 9 strains of Staphylococcus aureus have certain drug resistance and no lysis ability on escherichia coli. The Staphylococcus aureus phage has specific lysis spectrum for Staphylococcus aureus, and has strong lysis ability. The Staphylococcus aureus phages107 can be used for preparation of drugs for treating Staphylococcus aureus induced dairy cow mastitis and other diseases.

The invention relates to preparation of rumen bypass coated bacteriophage and an application of the rumen bypass coated bacteriophage in prevention and treatment of buffalo diarrhea. The rumen bypass coated bacteriophage is prepared by compounding six bacteriophages, comprising a staphylococcus aureus bacteriophage 52, a staphylococcus aureus subspecies bacteriophage B1, an escherichia coli bacteriophage T1, an escherichia coli bacteriophage T3, an escherichia coli bacteriophage S13 and a bacillus subtilis bacteriophage phi-e. The rumen bypass coated bacteriophage provided by the invention is added into a buffalo concentrate supplement according to the proportion that 30-70kg of the rumen bypass coated bacteriophage is added into each ton of concentrate. The rumen bypass coated bacteriophage is administrated to buffalo in a rumen bypass coating mode, the effect of preventing and treating buffalo diarrhea is ideal, and reference is provided for research of screening specific bacteriophages in the later period.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages including: podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142; staphylococcus aureus BP-13A with the preservation number of CCTCC M2016535; podoviridae BP-14 with the preservation number of CCTCC NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of CCTCC NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. Besides, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention discloses a staphylococcus aureus bacteriophage LSA2311 and application thereof. The staphylococcus aureus bacteriophage LSA2311 is of a wide spectrum type and can carry out lysis on staphylococcus aureus and drug-resistant strains thereof. An authentication result shows that the bacteriophage is of caudovirales myoviridae, the collection number of the bacteriophage is CCTCC NO: M 2020562, and the bacteriophage LSA2311 has a stable titer when pH is 6-11 and temperature is 40-50 DEG C. A complete genome sequencing result of the bacteriophage disclosed by the invention shows that the bacteriophage does not have virulence or antibiotic resistance and can transduce related genes, and safety generated when the bacteriophage disclosed by the invention is applied to treatment of pathogenic bacteria and bacteriophage in food can be proved from a genetic background. By use of the bacteriophage provided by the invention, the staphylococcus aureus in a milk sample can be effectivelycontrolled. Compared with antibiotics and chemical preservatives, the bacteriophage provided by the invention has the characteristics of being high in specificity, free from residues and safe.

The present invention describes a genetically modified Staphylococcus aureus bacteriophage VDX-10 comprising the DNA of the bacteriophage VDX-10 being altered by inserting a gene sequence that increases the ability of the bacteriophage to replicate faster as compared to unmodified VDX-10 bacteriophage; a method of producing the genetically modified Staphylococcus aureus bacteriophage VDX-10; and a method of treating infection in a patient by administering an amount of the genetically modified Staphylococcus aureus bacteriophage effective to eliminating the Staphylococcus bacteria cells, where the infection can be Ventilator-Associated Pneumonia (VAP) or bacteremia as incited by methicillin-resistant Staphylococcal aureus (MRSA) or methicillin-sensitive Staphylococcal aureus (MSSA).

The invention discloses a spray disinfectant containing a phage composition in a breeding environment and a preparation method and application thereof. The spray disinfectant comprises phage or its composition with a total concentration greater than 1010PFU / mL and a streptococcus suis lyase LY7917 with a concentration of 100.0 [mu]g / mL according to a volume ratio of 0.1-100: 1. The phage is derived from a breeding environment and is selected from one or more of escherichia coli phage Ecp2, escherichia coli phage E20-1 and staphylococcus aureus phage. According to the spray disinfectant, a spray sterilization mode is adopted, the synergistic sterilization effect of phage and lyase can be effectively achieved, the total number of bacteria on the ground of an animal house, in air and in a feeding trough is remarkably reduced, the overall disinfection efficiency is superior to that of a chemical disinfectant glutaraldehyde decyl methylammonium bromide solution, and the spray disinfectant is an environment-friendly disinfectant for the livestock and poultry breeding environment.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages, including podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142. staphylococcus aureus BP-13A with the preservation number of M 2016535; podoviridae BP-14 with the preservation number of NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. In addition, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention relates to the field of biological engineering, and in particular relates to lywallzyme (or catenase) of phage of staphylococcus aureus and an application thereof as an antibacterial material in preventing and treating bouine mastitis and controlling food pollution. The amino acid sequence of the lywallzyme of phage of staphylococcus aureus is SeqIDNO2. Zymin capable of efficiently killing staphylococcus aureus is developed by a bioengineering technique. The zymin can be used independently or with other agents to inactivate staphylococcus aureus specifically so as to provide a safe zymin source without toxic and side effects for preventing and treating bouine mastitis and controlling staphylococcus aureus pollution in food.

The invention discloses a bacteriophage biological amplification-real-time fluorescent quantitative PCR combined kit for rapidly detecting staphylococcus aureus and a method thereof. The combined kit comprises a phosphate buffer solution containing staphylococcus aureus bacteriophage LSA2311 and a primer pair tsp for real-time fluorescent quantitative PCR detection, a good detection effect can be achieved by combining phage biological amplification with a qPCR method to detect staphylococcus aureus in a food matrix, and the detection limit is 101 CFU / mL. Compared with a traditional culture method, the detection time is greatly shortened, and sample detection is completed within 2-3 h. According to the invention, an experimental basis and a theoretical basis can be provided for establishment of a staphylococcus aureus rapid detection method based on bacteriophage biological amplification.

The invention belongs to the technical field of animal infectious disease prevention and treatment, and particularly relates to a mutant staphylococcus aureus bacteriophage and application thereof. The staphylococcus aureus bacteriophage 4PHCISA25 separated in the invention is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M20211354. The invention provides an effect of the bacteriophage as a bactericide for preventing and treating staphylococcus aureus and a biofilm of the staphylococcus aureus, and provides a bactericide product with application potential for clinically treating staphylococcus aureus infection diseases. The staphylococcus aureus phage disclosed by the invention is wide in splitting range and strong in splitting capacity, and can be used for strongly killing methicillin-resistant staphylococcus aureus.

The invention discloses a staphylococcal phage composition and its application in medicines for staphylococcal infection diseases. Pharmaceutical compositions, feed additives, disinfectants and applications using the phage composition as the main active ingredient. The above phage composition has a strong lysing effect on bovine staphylococcus and can be used to prevent and treat diseases caused by bovine staphylococcus infection , compared with a single lytic bacteriophage, the composition greatly broadens its bactericidal range, increases its bactericidal activity, can improve the physique and disease resistance of dairy cows, and is low in cost and environmentally friendly.

The invention discloses a construction method of a recombinant adenovirus vector co-expressing SAL‑2 gene and hLYZ dual antibacterial gene, and the application of the recombinant adenovirus. The extra SAL‑2 gene and hLYZ gene were cloned into the pShuttle‑IRES‑hrGFP‑2 shuttle vector, linearized and recombined with the shuttle vector and co-transfected with the backbone vector pAdeasy‑1 into E. coli BJ5183 competent cells , making it perform homologous recombination in BJ5183, constructing the recombinant adenoviral plasmid Ad-SAL-LYZ containing the above-mentioned target gene; digesting the recombinant adenoviral plasmid with PacⅠ, and transfecting HEK293 cells through liposome-mediated transfection, High-titer recombinant adenovirus was packaged to obtain high-titer recombinant adenovirus; the joint inhibitory effect of SAL‑2 gene and hLYZ gene on the main pathogenic bacteria of dairy cow mastitis was evaluated under the mediation of adenovirus.

The invention relates to a preservative for medical foods. The preservative is prepared from, by weight, 1-9 parts of staphylococcus aureus phage powder, 1-9 parts of escherichia coli phage powder, 1-9 parts of Salmonella phage powder, 1-9 parts of shigella phage powder, 1-9 parts of listeria phage powder, 1-9 parts of proteus bacteriophage powder, 1-9 parts of botulinum phage powder and 4-6 partsof an antioxidant. The preservative can specifically inhibit pathogenic bacteria of common contaminated foods, effectively prevent pollution of the medical foods, prevent oxidation of lipids in the medical foods, and be the antibacterial, anti-oxidation, safe and non-toxic side effect preservative for the medical foods.

The invention discloses a strongly lytic Staphylococcus aureus phage RDP-SR-20001 and its application in poultry pathogenic Staphylococcus aureus infection. The present invention utilizes the double-layer plate method to obtain a Staphylococcus aureus BS‑20001 strain from diseased broiler lesion tissue of Qingdao Jimo broiler farm, and then uses Staphylococcus aureus BS‑20001 as the host to isolate gold from the farm sewage. Staphylococcus aureus phage RDP‑SR‑20001, the deposit number is CGMCCNo.21409. The Staphylococcus aureus phage RDP‑SR‑20001 provided by the present invention has a strong cracking effect on pathogenic Staphylococcus aureus BS‑20001 in the poultry breeding environment, and is used for industrial production of phages for pathogenic Staphylococcus aureus in the poultry breeding environment The control provides a phage source.

The invention relates to the technical field of bacteriophages, in particular to an acid-resistant and high-temperature-resistant staphylococcus aureus bacteriophage as well as a composition, a kit and application thereof. The staphylococcus aureus phage is a staphylococcus aureus phage Sa88P1 (Staphylococcus aureus phage Sa88P1), and the staphylococcus aureus phage is a staphylococcus aureus phage Sa88P1 (Staphylococcus aureus phage Sa88P1). The staphylococcus aureus bacteriophage has excellent acid resistance, has specific killing activity on staphylococcus aureus, and can provide a new bacteriophage strain source for industrial production of bacteriophage bactericides. The staphylococcus aureus bacteriophage also has high temperature resistance, has a survival rate of 60-70% after being subjected to a water bath at 65 DEG C for 2 h, has a titer of 106-107 PFU / mL after being subjected to a water bath at 75 DEG C for 2 h, can be prepared into various forms of products such as a feed additive, a drinking water additive, a feed, drinking water, a cleaning agent or a disinfectant, and can kill staphylococcus aureus in a relatively wide temperature range and pH range.

The present invention relates to the field of microorganisms, and specifically provides a new staphylococcal phage and its composition, preparation method and application. The phage is Staphylococcus aureus phage J1P1, and the preservation number is CCTCC No: M2016284; Staphylococcus aureus phage J1P2, The preservation number is CCTCC No: M2016285; the preservation number of Staphylococcus aureus phage J1P3 is CCTCC No: M2016286; the preservation number of Staphylococcus aureus phage J2-1P1 is CCTCC No: M2016287; The deposit number is CCTCC No: M2016288. The phage of the invention can prevent and treat human or animal bacterial infection diseases caused by various staphylococci, especially staphylococcus aureus, provide excellent phage resources for the development of new antibacterial preparations, and have good application and development prospects.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages, comprising: podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142. staphylococcus aureus BP-13A with the preservation number of M 2016535; podoviridae BP-14 with the preservation number of NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. In addition, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention provides a genetic engineering-modified staphylococcus aureus staphylophage lyase, the amino acid sequence of which is shown in SEQ ID NO:1. The invention also discloses a preparation method of the staphylococcus aureus staphylophage lyase, comprising the following concrete steps: (1) cloning the amino acid sequence shown in the SEQ ID NO:1 into a prokaryotic expression vector to obtain a recombinant plasmid; (2) transforming the recombinant plasmid obtained in the step (1) into host bacteria to obtain recombinant bacteria; (3) expressing the staphylococcus aureus staphylophage lyase by the recombinant plasmid; and (4) purifying the staphylococcus aureus staphylophage lyase obtained in the step (3). Multiple staphylococcus aureus can be specifically inactivated by independently using the genetic engineering-modified staphylococcus aureus staphylophage lyase or matching the genetic engineering-modified staphylococcus aureus staphylophage lyase with other compounds, thus providing a safe enzymic preparation source without toxic and side effects for staphylococcus aureus infection, particularly staphylococcus aureus caused dairy mastitis in the existing dairy farm control.

The invention relates to a bacteriophage and antimicrobial application thereof, in particular to a methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage and antimicrobial application thereof, and belongs to the field of bioengineering. The methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage is preserved in China Center for Type Culture Collection (CCTCC), located in Wuhan University of Wuhan of China, on September 17, 2015. The collection number is staphylococcus aureus bacteriophage qdsa002 of CCTCC M2015554. The Latin scientific name is staphylococcus aureus bacteriophage qdsa002. The bacteriophage has high splitting effect on staphylococcus aureus, especially methicillin-resistant staphylococcus epidermidis staphylococcus aureus. The preparation can be used individually or compounded with other drugs, and a safe bacteriophage product source free of toxic and side effects is provided for control of methicillin-resistant staphylococcus epidermidis staphylococcus aureus contamination.